#155: Ronan Levy, Co-founder & CEO of Field Trip Health

Today, I’m joined by Ronan Levy, co-founder & CEO of Field Trip Health.

Field Trip is redefining mental health and well-being through groundbreaking work in psychedelics and psychedelic-enhanced psychotherapy. Coupling the expansion of in-person clinics across North America with drug development and advanced research on plant-based psychedelics through Field Trip Discovery, Field Trip is pioneering evidence-based, legal therapies for depression.

In this episode, Ronan discusses the company’s approach to ketamine-assisted psychotherapy while detailing the key factors moving psychedelics into the mainstream. Plus, we explore the use cases for mental health, depression, PTSD, and more.

In this episode, you’ll learn:

  • How Field Trip is expanding its sales funnel & scaling the company
  • Tips for succeeding in a highly regulated & sometimes stigmatized industry
  • Ronan’s thoughts on becoming a lifestyle brand

Links & Resources

Ronan’s Links

Episode Transcript

This is a machine-generated transcript. Please excuse any errors.

[00:00:00] Ronan:
Until we recognize the reason we’re having a mental health crisis is a condemnation about how we’re living our lives these days—something in our society is not working. It’s a lot of things. It’s how we eat. It’s how we interact. It’s how much time we spend on our phones. It’s what we value.

What psychedelics are really attuned to is helping us wake up to the narratives we’ve all been sold and embraced, and start to ask the questions about, “Does that narrative serve me? Can I start to shift it?”

[00:00:38] Joe:
Welcome back to the Fitt Insider podcast. I’m your host, Joe Vennare.

Today I’m joined by Ronan Levy, Co-founder and CEO of Field Trip Health.

In this episode we discuss the company’s approach to Ketamine-assisted psychotherapy. Ronan details the key factors moving psychedelics into the mainstream. Plus, we explore use cases for mental health, depression, PTSD, and more.

Let’s get into it.

Hi, Ronan. Welcome to Fitt Insider. Thanks for joining us.

[00:00:59] Ronan:
My pleasure. Great to be here. I apologize in advance—you’ll probably hear some screaming kids in the background.

[00:01:08] Joe:
No worries at all. Just kind of adds to the overall experience.

As we jump into it, there is plenty to talk about; all types of interesting trends, a lot of what you’re doing at Field Trip, but maybe for folks who aren’t familiar, could you introduce yourself and tell us about Field Trip?

[00:01:24] Ronan:
Sure. Yeah. I’m one of the Co-Founders of Field Trip. I now serve as Chairman and CEO of Field Trip Health and Wellness Ltd. We are leading the access equation when it comes to legal, safe, psychedelic therapies. We have twelve Field Trip Health centers across North America, including one in Europe in the Netherlands primarily doing Ketamine-assisted psychotherapy given the whole legal-regulatory regime.

We’ve been at the forefront of this movement for the last four-and-a-half years or so. It’s been amazing to see the evolution from where the world was just five years ago to today. It’s been really mind blowing, and for good reason. These thereapies transform lives, and I really do believe there’s a kernel of wisdom in psychedelics that can transform how we live our lives in a really positive way.

[00:02:26] Joe:
Yeah, I think the, the space itself. And as you mentioned in the last few handful of years here, really coming onto the scene, I. With the willingness to explore and accept, or at least, you know, figure out a path to legalization, especially around mental health, trauma, and a host of other kind of ailments or benefits.

Right. Depending on how you think about it. I know your background a little bit, some experience. Course as an entrepreneur and founder, but specifically in the kind of cannabis space. So seeing this evolution, maybe once before of how we something that was, you know, stigmatized criminalized, and now moving more into the mainstream, do you think, or do you draw parallels between the cannabis industry and what’s happening with psychedelics and, and was that kind of a jumping off point to what you’re doing?

[00:03:13] Ronan:
Yeah. I mean, certainly there’s some parallels, but there are some differences. I mean the high level parallels are obvious. To classically stigmatized. Drugs medicines. However you want to describe them going from being once very verboten, to being very mainstream, accepted and venerated in many ways. The big difference in what we’re seeing is cannabis and the eventual acceptance, both medical and adult use of cannabis was driven.

Grassroots, you know, is political activism. It was people. Really like cannabis, you know, for either therapeutic or personal reasons, doesn’t really matter, pushing the agenda, pushing the agenda, pushing the sure, got traction as the world and prohibit cannabis idiot of, or, you know, even so much. So in Canada we had the, the, essentially the Supreme court declare that the criminal prohibition on access to cannabis was unconstitutional. Psychedelics. Bit different, you know, psychedelics is, is research led. It’s the research coming outta the Beckley Institute.

It’s the research coming outta Johns Hopkins. It’s the research being conducted by maps. It’s the phase two phase three clinical trials that are currently underway showing incredible safety, incredible efficacy that has really been driving the narrative around psychedelics. Now psychedelics has the benefit of cannabis having done its evolution over the last couple of years and everyone, everyone’s probably a little too broad, but a lot of people being like, oh, I thought that stuff was terrible out.

It’s not so bad. Cannabis will to build cannabis. But because the research is leading the conversation with psychedelics, it’s such a much easier conversation. There’s so many more politicians who are behind it. so many more scientists and the data and the evidence is so much more persuasive that it’s actually easier, an easier conversation, even though psychedelics seem far more extreme in terms of how we think about what drugs are okay with drugs are, are not OK.

And so it’s really cool to watch, you know, seeing it, seeing it happen and so quickly to be quite honest,

[00:05:18] Joe:
Yeah, you’re obviously on the inside and in many ways, as you said, like leading the charge with Field Trip and from the outside, looking in trying to make sense of it and maybe drawing parallels, even if they are incomplete or, you know, not the full picture with cannabis, With the research leading the way it’s like this, the, the research aspect, the, the kind of legalization aspect, and also the cultural aspect to the, the acceptance and the interest.

Can you kind of chalk it up to like why now, or the inflection point or how that research that was happening and, and kind of fell off for a period of time now there’s the resurgence that is bringing it to the forefront once again, or is it just kind of like a culmination that is kind of just serendipitous in a natural evolution?

[00:06:02] Ronan:
I’ve never used this analogy before, but I’m gonna use it’s, it’s kind of like laser it’s. It’s like light amplified by the simultaneous admission of radiation in many ways.

So what, what, what we have and, and why, why now is. You have a mental health crisis that’s of just incredible levels. You know, 25% of Americans over 18 are gonna be using antidepressants or equivalent at some point in their lives. These are just mind blowing numbers. You know, one in four people are gonna experience a mental health issue at some point in their lives, or we’re talking about billions and billions of people being affected with virtually no effective treatment options. And so you get this massive need. You’ve got cannabis, changing attitudes towards drugs, generally speaking and whole war on drugs. One of my favorite memes coming out of the Biden attitude. You have mental health coming into Vogue. Now, I don’t really like using the term mental health as it pertains to psychedelics or any of the dialogue. Cause it makes it sound like it’s something about your head and what we’re seeing more and more is that what we think of as mental health, as a, a holistic, you know, health decision it’s, what’s going on in your head.

It’s what’s going on in your guts, what you eat, it’s how you exercise. It’s how you live your life and all that kinda stuff. And when we talk about his mental health, Kind restricting it to the brain, so it’s not accurate, but we have this whole mental health thing happening. And, and recategorize how we think about that. You have calm and Headspace achieving billion dollar valuations. So it’s kind all mainstream right now. and then you have that running against that, running up into the current of the research, right? five years ago, maps was given breakthrough designation for its MDMA assisted therapy studies from the FDA, which we would think would normally be fairly reticent to do anything with MDMA.

You’ve got the research coming out. John’s Hopkins, looking at psilocybin for all these different, indications. and so all of these. Things are landing on an inflection point right now. And then you throw a, pandemic, which messed with literally everybody’s heads over the last two and a half years.

And it’s kinda no surprise that psychedelics are very in vogue right now. but I think we’re just at like the, we’re just scratching the surface to be quite honest, like I’m in this every day, you’ve been part of the conversation a bit now for a while. So it kind of seems like everybody knows what we’re talking about, but the truth is like, The other 97 of the population still think psychedelics are.

[00:08:39] Joe:
For sure. And, to that point, like with the, you know, moving this conversation more into the mainstream and, you know, Asked majority of people, like you said, don’t have this awareness and still have a perception of it that, you know, it’s super dangerous. And frankly, some people still have that of, you know, cannabis.

So it it’s kind of no surprise how much of this work is purely that education. Destigmatization resources. And how do you that? Almost, you know, I don’t know if it’s, it’s both separate from, but also within the company itself. I don’t know if you, you know, do you think of yourself as like that’s part of the mission we have to drive this education and awareness, or do you feel like we have to be part of that broader conversation?

[00:09:22] Ronan:
It’s hard to dissect, you know, whether we’re driving it or we have to be a part of it. I think we’re driving it. If, if you look at the proportion of media mentions pertaining to psychedelics, that include Field Trip, we count for about 40 to 50% of all media mentions as it. pertains to psychedelic companies.

So we’re very much driving it and something that’s of a personal passion to me, which is, I think it’s one of the things probably I’ve learned throughout life, but also saw in the cannabis industry is that it can get over medicalized or over that’s there’s. You know, as it pertains to psychedelics, it’s like, it’s not just about treatment resistant depression or, yesterday, came out a, this is neuropharmacology. And that’s a completely incomplete answer. You know, it’s, it’s a cultural revolution. If we think of psychedelics just as a medical treatment, we’re setting up to in of its impact, definitely.

But we recognize that the we’re mental health crisis is not a of psychiatry. It is partly a failure psychiatry, but it’s really a condemnation about how we’re living our lives. These days, like something in our society is not working. It’s a lot of things. It’s how we eat. It’s how we interact. It’s how much time we spend on our phones.

It’s what we value. You know, I, I was raised on the neoliberal dream of go to school, work hard, get good grades, get the job, you know, marry the beautiful woman by the car, by the house and your life is perfect. And I’ve been fortunate that I did all of that. And lo and behold, my life still isn’t perfect.

And I’ve got all sorts of, you know, things. I gotta work through nothing that leads to treatment resistant, depression or severe anxiety. It’s part of life, you know, and, And I think what psychedelics are really attuned to is helping us wake up to narratives. We’ve all been and embraced and the questions that.

And that’s the most important part of this conversation. It’s not about the jog. It’s not about the, the, the five HD two, a serotonin receptor that gets agonized by silt. It’s about waking up to what’s going on in our lives. And so you either have, you know, the doctors saying it’s all about the receptor binding, and then you have, you know, the, the hippies being about it’s all about God and the spirit.

And the answer is. All of that and more. And so I take it personally and I’ve really tried to help position field, as the company that says, yes, it’s where’s as part of our role as Field Trip.

[00:12:10] Joe:
Yeah, I really appreciate the, the kind of nuance that you share there, because I do think oftentimes it’s described as almost binary, right? That this it’s a kind of healthcare, mental health solution or it’s, you know, just a pure recreational pursuit and where, and how those things overlap, I think is, is.

Part of that, what we’re still trying to figure out, frankly, and, and how we do that in a way that we can introduce it to society, to avoid. And, and maybe you have a perspective on this. Like just the idea that it is just free flowing and you can walk into, you know, like you do, cannabis store and grab it and go on your way and experience.

However you want to, when you talk about something where the experience itself, the, therapy, the coaching, how it’s administered is such a big part of that. How do you bridge those two worlds to avoid this? You know, for lack of a better word, kind of like free for all, all access versus like this controlled and kind of nuance back to your your point experience.

[00:13:07] Ronan:
You know, I’m a lawyer by training. I, I spent, I’m still qualified actually And, and one of the things I’ve. People are gonna get around it and unintended side effects and we’ve. And so I’m actually kind of a believer that a free for approach is probably the best way, which is we still need the research. At the same time, you know, people like myself, it’s like, I’m, I’m, I’m educated, I’m informed, I’m experienced. I probably know what I’m doing more so than any regulator is going to have an or any doctor who’s advising a regulator is going to have an opinion. And so let’s, let’s kind of let it, see how it plays out and learn.

I mean, this is design thinking, right? You put it out there, you see what happens, you evolve, you know, instead of trying. Regulate for every potential harm or risk, which is what often tends to happen. Let’s be responsive. Let’s let people be responsible, you know, take responsibility for their own actions, and, and evolve that way.

Are there going to be unintended consequences? Absolutely. Are people gonna get hurt probably. Is that, I’m not gonna even say sacrifice. Is that a decision I’m willing to make? Yes, because everything has consequences and I see it so often in social media where people are like, you know, if you believe that progress should still happen, not withstanding that there.

Some incident you described as callous, and it’s like part of the conversation. And this goes back to the conversation about nuance is like I can be for progress and want to keep moving forward. And still have empathy and sympathy for the things that went wrong and hold them at the same time. But most people think it’s impossible.

You’re callous capitalist, or you’re, it’s like, and capitalist at the same time and go hand in hand. And truthfully, until we accept that both of those can coexist, we’re gonna keep running into problems over and over again. I know that’s a long kinda diverted way of answering the question, but it’s like, I, I do believe we should.

You know, experiment and learn instead of trying to over anticipate every potential consequence.

[00:15:32] Joe:
No, I, I appreciate. Insight and kind of framing that up. And I think that At this point, at least not a right answer or certainly not a, a known answer in terms of how it’s going to play out. So being willing to, and, you know, taking the, if you want to call them chances, right. Or, or just exploring how we best implement this, I think it’s, at this point feels inevitable that it’s going to happen.

So it’s just a matter of how it plays out and along the way, right. We, we. Necessarily predict every outcome. and kind of to that point, we’ve talked about it at a high level, you know, just the overall kind of shift in psychedelics more broadly, but I definitely want to tie it into what you’re, what you’re actually doing at Field Trip and how you’ve, you know, from identifying that this shift was coming to saying, Hey, this is what we’re able to start with.

And, you know, implement at this point, and this is where we kind of see it going. So maybe just start with, what is the experience today when somebody kind of walks into a clinic or accesses Field Trip and, how is that growing or, or doing as a business?

[00:16:32] Ronan:
Yeah, sure. So what we’ve done with Field Trip is, as I’m sure is evident in this conversation, tried to blend the best of all worlds into a single experience. And so we’re very medically rigorous and, and there’s a. On site and you go through a psychiatric screening to make sure Ketamine assisted therapy is appropriate for You onsite.

When you come into our clinic, there’s medical there’s therapists, there’s just about everything you would think you want to circumstance in this kinda sphere we have on site. On the other hand, you walk into our clinic and it looks nothing like a clinic. It looks like a Bohemian chic apartment. A lot of people opine that they’d like to live in our clinics, cuz they’re nicer than their apartments. And we invest very heavily in that because we want to breed a sense of and safety, and, and trust.

So people are at ease when they’re dealing it with us any step of the way, which. Contrary to most doctor’s offices. If you think about it, right. They’re very efficiency, you know, fluorescent lights, fast space frenetic, you know, that’s not the kind of experience we have. You know, we, we have always strived to have a one woo factor, so we’re not woo woo.

But we’re one. Woo. Which is like we’re, we’re paying homage. To, you know, a lot of the ceremonial and indigenous traditions that came before without leaning into it too much, you know, we have a no shaman rule. There’s no shamans at Field Trip. Right. again, we want to position this in a way that opens it up to a lot of people in our Western society who probably. Somewhat skeptical, not necessarily wrongfully, so, of, of things that are a little too out there in terms of ceremonial practice or, or non science. and so when you come, the process is, is you start with, you know, getting whatever information you need from our staff. we do a psychiatric screening to make sure therapies are appropriate for. Assuming everything’s a go, you come in, you meet with your therapeutic team, you get comfort with them. You come in for your first session a few days later. And what really differentiates us from most operators out there is that we have a heavy focus on integration. So after every two Ketamine sessions, there’s a purely dedicated integration session.

So all the insights awareness, that come outta the experiences. You know, there’s an opportunity to them and them into your life. There’s an opportunity to take advantage of that window of neuroplasticity to adopt new habits, new practices, new outlooks, new mindsets, crystallize, and that’s roughly the experience of field is it’s professional.

But very friendly and deeply focused on integration experience. As far as I’m aware, the outcomes, anxiety, Milds. Those benefits often last for four months or longer, we’re just finalizing some research that we’re, it really is quite impressive.

[00:19:45] Joe:
Yeah, it’s kind of not only standardizing in a way, but also, branding, the whole experience is, is much more appealing and something that you want to participate in as opposed to going to the doctor’s office, which is the complete opposite of that.

[00:19:59] Ronan:
A hundred percent. Yep.

[00:20:01] Joe:
And then to this point, you mentioned kind of like the, the four month mark and maybe even more, is there a kind of recommendation in terms of number of sessions or a limit to the number of sessions, at least for what we note at this point,

[00:20:14] Ronan:
Yeah. So the results we’re seeing typically involve six Ketamine sessions interspersed with three integration sessions delivered over the course of three to four weeks. and so that’s generating the best outcomes, but we recognize that that’s very time intensives, inexpensive accommodate. Adjust those programs as you know, a good of flexibility on don’t recommend four sessions results.

[00:20:49] Joe:
And then in terms of access or legalization, is it a state by state issue at this point? Is it, it limited as far as where you’re able to roll this out and, and how do you see that kind of expanding.

[00:21:01] Ronan:
No, actually we can do it everywhere. So many people, it comes as a surprise to many people, but Ketamine is an FDA approved medicine. It was initially approved, I think, somewhere around 1970. as an anesthetic and it’s still used in hospitals. In fact, it’s so safe and so frequently used that if you and broke a, a bone or you just like dislocate a shoulder or whatever, take, ER, odds are they’ll Ketamine over other form of anesthetic.

That’s the profile. We’re dealing medicine, medicine, as long as you have a doctor with a DEA license. They can prescribe. and that goes across all 50 states, probably, you know, the, other territories as well, but we haven’t expanded that far yet. and, and so there’s no restrictions on that psilocybin that we do in the Netherlands.

Obviously we can only do that in the Netherlands right now. We could conceivably do it in Jamaica. And there’s a couple of other jurisdictions where psilocybin mushrooms are legal. We’re not there yet. but in, the lower 48, Ketamine assisted therapy is available anywhere. You know, there has to be a medical diagnosis, so you can’t walk in and just be like, Hey, I’m feeling grades.

I’ve got no issues. I just want to get high. That’s not gonna pass, our, our medical muster. But the truth is is like, if you’re not dealing with some kind of adjustment issues over the last two and a half years, you’re probably not paying attention. So there’s usually basis to treat a lot of people. Cause everybody’s got stuff to work.

[00:22:25] Joe:
And then in terms of, and you may have mentioned this, so apologies. how many locations are there now? And I guess how many do you envision, rolling out even in the near.

[00:22:33] Ronan:
Yeah, right now, there are, 12 locations, eight in the us, three in Canada and one in the Netherlands right now we’re focused on, on just operating the existing infrastructure, but we’ve also recently launched Field Trip at home, which is Ketamine therapy from the we’re seeing is that. There’s certain people who want the, the comfort and experience of doing this in a center, specifically designed for psychedelic therapies. and there are a lot more people who don’t live within 20 miles of any of our clinics, or prefer the comfort of doing it from their home. And so we launched our Field Trip at home programs delivered there, And so our focus right now is up to this point. We’ve. Trying to prove this, this can be done safely, effectively generate great results and there’s demand for it.

We feel we’ve, satisfied, you know, those objectives now it’s about scale and access. And so going forward, you’re gonna be focused on Field Trip at home. We’ve got our app trip, which is out there, which is designed to support the experience, whether you’re doing it on your own. Legally or otherwise, with meditations music, protocols, all that kinda stuff.

And so we’re gonna focus more on There’s a huge medical need, but clearly the cultural movement is moving a lot faster than the medical, establishment is around this. and again, we really think it’s important to try and set a narrative in a discourse around any psychedelic use, whether medical, therapeutic, or totally recreational that people are and thoughtful and responsible, how do this kinda stuff.

And so that’s gonna become a much more central focus of field. Providing people with the tools, providing people where access were medically appropriate, and then also providing people with the spaces. If it, if that’s of, you know, importance to the individual at the time,

[00:24:13] Joe:
Yeah. And we, we talked about how, especially during the pandemic, you, you know, are encountering a lot of these mental health or otherwise kind of, issues in your life face to face, certainly telemedicine from a outcome of the pandemic. A lot of people now realizing that, Hey, we can do much more of these things at home.

So I think that also kind of accelerating this shift to. The at home Ketamine treatment. When you talk about now expanding access, you have the clinics, you have the app, you have the at home treatment. What happens next? Right? Is both, is it a partially, a waiting game as other drugs become destigmatized?

Is it, Hey, what other services can we launch? Whether that’s in person or at home or digitally, how do you think about navigating that path while things still have to play out right at the, the kind of legal.

[00:25:06] Ronan:
Answer is yes. To all of those, to be quite honest. So, you know, effort into building awareness for what the response and demand was and, and the response to both have been fantastic. And so really now it’s about, pouring fuel on the fire to create awareness for those, and then really create engagement with them. Whereas before we’re just kinda letting them grow organically. so, so that’s one focus.

Another focus is expanding the funnel. So primarily we treat people with depression, anxiety, and PTSD these days. you know, we’re looking very actively at expanding to other indications. so alcohol use, there was just a came on for Ketamine is actually very effective as well. Other have shown so who we can and what indications is part of importantly, you know, gearing up for MDMA, maps, expects approval for MDMA assisted therapy from the FDA sometime late next year.

Even though it seems like a far away, at the end when you get to my age, that’s gonna like that. and so it’s going to gear and prepared and develop clinics designed to support M assisted therapy and relationship with maps. I certainly look at us as the forefront in terms of their commercialization strategy as well.

So all of those are going to be the focus over the next next 18 months or.

[00:26:38] Joe:
Yeah, it’s, it’s an exciting time. I think, as we think about, you mentioned, you know, a year or two, that’s, you know, a blink of an eye. And so I think, laying that groundwork, continuing to do the work that you’re doing, as we get towards the end of the conversation, one thing that I think it’d be interesting to get your perspective on, and maybe this isn’t the case with psychedelics, but as we’ve kind of seen.

Cannabis bringing that full circle almost to, to where we started the conversation. how much of the experience can a brand own, if that’s the right word from creating their own strands. Right. And having their own, pipes or, you know, packaging or clothing or extensions of the brand that way, as well as like the physical locations themselves, where they’re selling these, all the different, types of, whether it’s the drugs themselves or paraphernalia, everything that goes along with it.

And, and almost to the extent where it becomes a lifestyle brand. And you’ve talked about you. Thinking of this as, Hey, we want to break down as many walls as possible. is it important or how important is it to think about how we can extend or expand the brand as we do this to kind of control or own that experience versus building a platform and making it accessible and it serves its purpose that way?

I think. is it possible or is it even right for somebody to kind of own, Ketamine treatment or psilocybin or that experience, or should it be kind of more accessible and approachable and, democratized almost.

[00:28:11] Ronan:
I think it should be democratized and I don’t think anybody at least within Field Trips, certainly. I don’t want to.

And I think that’s absolutely critical for the psychedelic industry, because it is lifestyle that we’re talking about. It’s the lifestyle that we all lead that has led to the mental health crisis. That’s to say like, psychedelics are, are kind of like the catalyst to shift the lifestyle. So you kind of just crack the egg, but don’t have a bowl to drop it into.

You’re doing people a bit of a disservice. Now a lot of people can be responsible and being like, OK, my eyes have been open. Now I can make a shift on my own. But I think it’s important. And certainly I feel passionate about being like, okay, now your eyes have opened, you know, you started the trend towards healing or however you may want to describe it.

How do you support that? How do you sustain that? And, and so at Field Trip, we’re trying to build an ecosystem, not necessarily to be exclusive, but because. It is synergistic, right? You go through Ketamine Orsic and assisted therapy experiences. You’re done. Now, what do you just go back to regular life? Do you surround yourself with all the friends that made you miserable in the first you, or do you a community of people that you can now share your experiences with and when pops up through months from now and all of your friends think you’re.

Crazy because you went to, duke Ketamine assisted therapy. Is there a network of people you can now turn to You know, who understand it and be like, oh, that’s really interesting, Joe. I had a similar experience. Here’s what I took away from that that may help you like, oh, by, by the way, next week, we’re going to other ship, you know, in Toronto to do some sauna and, cold plunges and and a breathwork session.

You want to come. It’s like all of that matters So if you’re not creating at least the the off-ramps or more accurately, the on-ramps to these other experiences. Psychedelics aren’t going to achieve what they, I think they could achieve. and a Field Trip won’t do be doing as much as it could be. so I don’t think that’s owning it.

You know, it doesn’t stop anybody else from doing something similar. What we’re focused on is creating these opportunities and then tracking people and showing that, Hey, when you do this and this and this, and we’ve curated, what we think is the best experience you generate these outcomes and your life is this much better. That will stand by itself and that doesn’t involve IP or lines. That’s.

[00:30:44] Joe:
Yeah. Huge opportunity. And obviously you put it much more succinctly than my question from the onset, but that, you know, facilitating that community and providing those points of intersection and continuing to, you know, push that forward. I think, not being discussed a ton, right. From the, from the outside looking in, but a massive opportunity to, to drive this forward and, and play a role in, you know, Whether it’s destigmatizing or, normalizing the conversation around these types of experiences and this culture and, you know, the people that are choosing to pursue it.

And I think, you know, in wrapping up, maybe just one more question, you may have touched on this as we think about, you know, MDMA and what comes after that. But is there anything that we should look out for? Anything that you’re particularly excited about, from the business or, or, you know, even if it’s no announcements that you can reveal anything, we should be keeping tabs.

[00:31:35] Ronan:
Yeah, absolutely. So, I mean, we’re, we’re working hard to really expand the functionality. Of The content of the trip app. so I think in the coming weeks and coming months, you’ll see some announcements coming out around that, that I are going to enhances in the works leverage. You know, refreshed app experience. Can’t share too many details about that, but I think it’s really exciting stuff. And it all speaks to what I’ve been saying, which is this is a lifestyle decision. And so it starts with the treatment protocol, but that’s just the first step.

The rest of it is where I think the real magic can happen. and so you’ll see a lot more of that conversation and a lot more work from Field Trip in that.

[00:32:21] Joe:
Perfect. A lot to look forward to, and we’ll get you out here on this: where should people go to learn more? What’s the best access point or starting point?

[00:32:30] Ronan:
Yeah. FieldTripHealth.com is our website. On socials it’s @FieldTripHealth. If you want to follow me, I’m @RonanDLevy.

Personally, and it also pertains to Field Trip, we’ve got some fun stuff coming out. I just published a book called The Trip Journal. So if you’re doing psychedelics, or meditation, or anything along those lines it’s really a guided tool, much like The Five Minute Journal—I’m sure many people listening to this are familiar with The Five Minute Journal—to help your journal your experiences and start the integration process. So that’s coming out.

We’ve got a documentary coming out, probably sometime toward the end of this year, called Ordinary Trip, where I basically put myself through a whole bunch of experiences and see what happens. I think that’s going to be really fantastic. Next year I have a book called the Ketamine Breakthrough coming out with Doctor Mike Dow.

So lots of fun stuff coming out personally and for the company.

[00:33:27] Joe:
Yeah, making moves. It’s awesome to see, and we are certainly excited about it. We’re excited to share this and share the conversation, and encourage folks to check it out. So I appreciate you making some time today and sharing your insights.

[00:33:38] Ronan:
It’s been my pleasure. Thanks for having me on, Joe.

Get the latest health and fitness industry news

Keep up with industry news, trends, investment activity, and job openings — in one weekly newsletter.

    No thanks.